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Murine erythropoietin-responsive Rauscher Red S-l.5 cells were used to determine the contribution of glycosylation to the size and function of 
the erythropoietin receptor. The half life of the receptors was determined to be 4 h. The number of receptors was not significantly decreased in 
cells treated for 48 h with inhibitors of glycosylation (tunicamycin, glucosamine or swainsonine) and their affinity was slightly enhanced in tunicamy- 
tin- or glucosamine-treated cells. Erythropoietin was cross-linked with two proteins of 104 and 86 kDa. Their molecular masses were not significant- 
ly reduced in cells treated with the glycosylation inhibitors. When immunoprecipitated cross-linked receptors were digested with endoglycosidases, 
the molecular masses of both proteins were only slightly modified giving values of 100 and 82 kDa. Thus we can conclude that the proteins cross- 
linked to erythropoietin are very weakly glycosylated. 
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1. INTRODUCTION 
Despite extensive studies, the.Epo mode of action re- 
mains largely unknown. We [1,2] and others [3-61 have 
shown that Epo binds to high affinity membrane recep- 
tors on erythroid cells. Cross-linking experiments have 
shown that Epo associates with two proteins of near 
100 and 85 kDa [l S-71. The relationship between 
these two proteins remains unknown but it has been 
suggested that the smaller component could be a pro- 
teolytic fragment of the larger one [7]. A cDNA coding 
for an Epo binding protein was recently cloned from 
murine erythroleukaemia cells [8]. It encodes a 55 kDa 
protein with a single hydrophobic domain located near 
the middle of the molecule. The relationship between 
the 100 and 85 kDa proteins evidenced by cross-linking 
experiments and the 55 kDa protein corresponding to 
the cloned cDNA remains to be established. As sug- 
gested by D’Andrea et al. who cloned this cDNA, the 
85 and 100 kDa proteins could be derived from the 
55 kDa protein by glycosylation [8]. We tested this 
hypothesis and we show in this paper that the 85 and 
100 kDa proteins exhibit very little, if any, 
glycosylation. 
other reagents were from Sigma (St. Louis, MO). Human recombi- 
nant Epo (spec. act. > 10’ U/mg) was iodinated using Iodogen as 
described in [3]. 
2.2. Cell culture and labeling 
The Rauscher erythroleukaemia cell line Red 5-l .5 kindly provided 
by Dr N. de Both was used. These cells differentiate under Epo action 
[9]. They were cultured in cy-modification of Eagles medium contain- 
ing 5% fetal calf serum. Epo labeling of the cells, Scatchard analysis 
and cross-linking with disuccinimidyl suberate were done as previous- 
ly described [1,2]. 
2.3. Immunoprecipitation of cross-linked Epo-receptor complexes 
and enzymatic deglycosylation 
2. MATERIALS AND METHODS 
2.1. Materials 
The cells were solubilized in 25 mM Hepes buffer pH 7.8 contain- 
ing 150 mM NaCl, 5 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 10 mM benzamidine, 10 /g/ml leupeptin, 10 pg/ml 
aprotinin and 1.5% Triton Xl00 using 1 ml of solution for 10’ cells. 
After 15 min on ice, the mixture was centrifuged at 150000 x g for 
30 min and the cross-linked Epo-receptor complex was im- 
munoprecipitated using Protein A-Sepharose beads and a rabbit an- 
tiserum raised against human recombinant Epo. Immunoprecipitated 
materials bound on the beads were resuspended in 50~1 of 50 mM 
sodium phosphate buffer pH 6.00 containing 0.1% SDS, 80 mM 
dithiothreitol, 1 mM 0-phenanthroline, 1 mM phenylmethylsulfonyl 
fluoride, 10 fig/ml each of aprotinin, leupeptin and pepstatin, 1% 
Triton Xl00 and 0.02% NaNn. The suspension was incubated for 1 h 
at 37°C with 50 mU of neuraminidase from Arthrobacter ureafa- 
ciens, then 5 mU of endo-c&V-acetylgalactosaminidase and 300 mU 
of endoglycosidase F were added and the incubation was continued 
for 18 h. After the addition of Laemmli sample buffer, the prepara- 
tion was boiled and analysed by SDS polyacrylamide gel elec- 
trophoresis according to Laemmli [lo]. 
The glycohydrolases were from Boehringer Mannheim. The cell 
culture products were purchased from Gibco (Paisley, Scotland). All 3. RESULTS AND DISCUSSION 
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3.1. Effect of glycosylation inhibitors on Epo binding 
Our goal was to determine the effects of glycosyla- 
tion inhibitors on the Epo binding ability of the recep- 
tors and on their molecular weight. It was therefore 
necessary to determine the half life of the receptor to 
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ascertain that all the receptors present on the cells after 
incubation with the glycosylation inhibitors were syn- 
thesized during this incubation time. For this purpose, 
protein synthesis was blocked by treating the cells with 
0.5 mM cycloheximide for various times and the re- 
maining Epo specific binding sites were measured 
(Fig. 1). Half life of the receptor was so determined to 
be 4 h in Red 5-1.5 cells. Because all the experiments 
were made by preincubating the cells 48 h with the 
glycosylation inhibitors, all the Epo receptors present 
on the cells were synthesized in the presence of the in- 
hibitors. Tunicamycin and glucosamine which inhibit 
N-linked glycosylation and swainsonine which inhibits 
N-linked oligosaccharide processing were used. 
Tunicamycin was highly toxic at the doses commonly 
used, so we determined the minimal dose able to block 
glycosylation (tested by mannose incorporation into 
trichloracetic precipitable material) with minimal ef- 
fects on overall protein synthesis (tested by methionine 
incorporation). At the chosen concentration 
(0.2 pg/ml), tunicamycin inhibited mannose incorpora- 
tion by 90% and methionine incorporation by 50%. 
Lower concentrations only partly inhibited mannose in- 
corporation whereas higher concentrations trongly in- 
hibited protein synthesis (data not shown). 
Glucosamine (10 mM) inhibited mannose incorpora- 
tion by 95% and methionine incorporation by 30% 
whereas swainsonine (1 pg/ml) did not change 
methionine or mannose incorporations. Fig. 2 shows 
that the glycosylation inhibitors did not inhibit Epo 
binding. The number of Epo receptors per cell was 870, 
890, 735 and 505 in control cells and in cells treated 
with swainsonine, glucosamine or tunicamycin, respec- 
tively. The decreases observed in tunicamycin (42%) 
and in glucosamine (16%) treated cells was of the same 
order as the overall protein synthesis inhibition. In- 
terestingly, the glycosylation inhibitors increased the 
apparent affinity of the receptors since the Kd changed 
from 340-350 pM in control and swainsonine-treated 
cells to 220 and 204 pM in tunicamycin- and 
glucosamine-treated cells, respectively. Whether this ef- 
fect was due to lack of glycosylation of the receptor 
itself or of other proteins surrounding the receptor re- 
mains to be determined but it is interesting to notice 
that the removal of sialic acid from Epo itself increases 
its affinity for the receptor [4]. It is conceivable that the 
presence of negatively charged groups both on the Epo 
molecule and on the receptor itself or in the vinicity of 
the receptor decreases the affinity of Epo for its 
receptor. 
3.2. Contribution of glycosylation to the molecular 
masses of the Epo cross-linked proteins 
As can be seen in Fig. 3A Epo could be cross-linked 
with two proteins of A4, -85 and 100 kDa. This result 
confirms previously published observations [ 1,5-71. 
Cell incubation with tunicamycin or glucosamine did 
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Fig. 1. Determination of the half life of Epo receptors. Cells were 
incubated with 0.5 mM cycloheximide for the indicated times. Epo 
specific binding was determined by adding 800 pM “‘1-Epo during 
the last 45 min of incubation. 
not modify the molecular masses of these proteins 
showing that they did not contain N-linked car- 
bohydrates. To ascertain this result and to test the 
presence of O-linked carbohydrates, we submitted 
cross-linked products to endoglycosidase action. Initial 
attempts to do this using all the solubilized products 
were unsuccessful because of the presence of proteases 
which degraded the cross-linked complexes. Therefore 
we used immunoprecipitated complexes. Fig. 3B shows 
that the molecular masses of both cross-linked com- 
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Fig. 2. Scatchard analysis of Epo binding to cells incubated with 
glycosylation inhibitors. Cells were cultured for 48 h with 0.2 pg/ml 
tunicamycin (closed triangles), with 10 mM glucosamine (open 
triangles), with 1 pg/ml swainsonine (open circles) or without 
inhibitor (closed circles). Scatchard analyses were then carried out in 
the presence of the inhibitors as previously described [1,2]. 
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Fig. 3. Contribution of carbohydrates to the molecular mass of the proteins cross-linked with Epo. (A) Control cells (C) and cells cultured 48 h 
with glucosamine (G) or tunicamycin (T) were labeled with 12sI-Epo and cross-linked with disuccinimide suberate before analysis by SDS-PAGE. 
(B, C) Cross-linked “‘1-Epo-receptor complexes from untreated cells were immunoprecipitated with anti-Epo antiserum, incubated without (C) 
or with (DC) glycohydrolases as described in section 2 and analysed by SDS-PAGE using 7.5% (B) or 12.5% (C) polyacrylamide gel. Numbers 
indicate the molecular masses in kDa of marker proteins. 
plexes were lowered after deglycosylation decreasing 
from 144 kDa to 121 kDa for the larger size complex 
and from 124 kDa to 102 kDa for the smaller size com- 
plex. Epo being a highly glycosylated protein with both 
0- and N-linked carbohydrates, the efficiency of the 
deglycosylation reactions was assessed by examining 
Epo deglycosylation. Small aliquots of the reaction 
mixture were analysed on 12.5% polyacrylamide gel to 
verify the efficiency of the carbohydrate removal reac- 
tions (note that, as always reported, the efficiency of 
the cross-linking reaction was low). Fig. 3C shows that 
Epo molecular mass decreased from 34 kDa to 19 kDa 
after glycohydrolase action. Since the reported 
molecular mass of Epo protein moiety is 18 399 Da 
[ 111, we could estimate that deglycosylation was com- 
plete. Thus nearly all the molecular mass lowering of 
the cross-linked complexes could be attributed to Epo 
deglycosylation. After allowing for the contribution of 
removing carbohydrate from Epo, the molecular 
masses of the Epo cross-linked proteins changed only 
very little after deglycosylation: in 5 experiments we 
calculated values of 104 + 5 kDa and 100 + 6 kDa for 
the larger size protein and 86 + 4 kDa and 82 f 4 kDa 
for the smaller size protein before and after 
deglycosylation respectively. 
3.3. Conclusions 
Our results show that glycosylation of the receptor is 
not required for Epo binding. We have also 
demonstrated that the 100 and 85 kDa proteins cross- 
linked with Epo are very slightly if at all glycosylated. 
Consequently these proteins cannot be derived by 
glycosylation of the 55 kDa protein whose cDNA was 
cloned recently [8]. The relationship between these pro- 
teins remains to be determined. Other covalent 
modifications can increase the size of a protein: ubi- 
quitin fixation for example was reported for some 
membrane receptors (see [12] for review). Alternatively 
the 85 and 100 kDa proteins may not be related to the 
55 kDa protein. Authors have reported results sug- 
gesting that the Epo receptor may be a complex of 
disulfide-linked proteins [1,6,13]. It is possible that 
Epo could be cross-linked to proteins of the complex 
(the 85 and 100 kDa proteins) different from the true 
Epo binding moiety (the 55 kDa protein). We are cur- 
rently testing this hypothesis. 
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